Cognitive Research Corporation

• Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)

  Collaborator, Phase 3, Terminated, 13 people, 27 Dec 2022

• NCT05313386

  Collaborator, Phase 2, Withdrawn, 0 people, 6 Apr 2022

• NCT05276830

  Collaborator, Phase 2, Terminated, 5 people, 11 Mar 2022

• NCT05271552

  Collaborator, Phase 3, Completed, 151 people, 9 Mar 2022

• NCT04970342

  Collaborator, Phase 1, Completed, 13 people, 21 Jul 2021

• NCT04470050

  Collaborator, Phase 1/2, Completed, 225 people, 14 Jul 2020

• NCT04276883

  Collaborator, Phase 3, Completed, 380 people, 19 Feb 2020

• NCT04268303

  Collaborator, Phase 3, Completed, 380 people, 13 Feb 2020

• NCT04010305

  Collaborator, Phase 1, Completed, 135 people, 8 Jul 2019

Sources: clinicaltrials.gov